

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

Next Science SPP – ASX grants waiver

Sydney, Australia Thursday, 7 September 2023, Next Science Limited (ASX: NXS) (**Next Science** or the **Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to announce that ASX Limited (**ASX**) has granted Next Science a waiver from Listing Rule 7.1 to the extent necessary to permit Next Science, without shareholder approval, to issue shares under a share purchase plan at an issue price of A\$0.42 per share (**ASX Waiver**).

The ASX Waiver has been granted on the following conditions:

- the issue price of the shares offered under the SPP will be no less than the \$0.42 issue price of shares to be issued on 6 September 2023 under the placement announced by the Company on 31 August 2023; and
- the number of shares to be issued under the SPP is not greater than 30% of the number of fully paid ordinary shares already on issue.

The Company announced the opening of a share purchase plan (**SPP**) on 1 September 2023.

The SPP is open to eligible Next Science shareholders to apply for up to A\$30,000 of new fully paid ordinary shares in Next Science (**SPP Shares**) without incurring brokerage or other transaction costs.

SPP Shares are being offered at the issue price under the placement announced to the market on 31 August 2023 (being A\$0.42).

Eligible shareholders may apply online via the Next Science SPP Offer website at:

<https://spp.nextscience.com/>

Eligible shareholders can also access the SPP Offer site by scanning the QR Code below with their smart device:



NEXT SCIENCE®

Indicative Timetable**

| Event | Date, 2023 |
|--|-----------------------------------|
| Record Date for the SPP | 7.00pm Wednesday, 30 August |
| Announcement of SPP | Thursday, 31 August |
| Opening - SPP and US Placement | Friday, 1 September |
| Settlement of the Institutional Placement | Tuesday, 5 September |
| Allotment of New Shares under the Institutional Placement | Wednesday, 6 September |
| Closing Date - SPP and US Placement | Monday, 18 September |
| Allotment of New Shares under the SPP and US Placement | By Monday, 25 September |
| Shareholder Meeting to approve the issue of shares to Next Science substantial holder, Walker Group, and Director participation in the Placement | Est. late October |
| Issue of Walker Subscription Shares and Director Placement Shares | 5 Business Days after the Meeting |

*** These dates are indicative only and are subject to change. Next Science reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Next Science reserves the right to extend the Closing Date, accept late applications under the SPP Offer (either generally or in particular cases), and to withdraw or vary the Placement, the US Placement or SPP Offer without prior notice. Any extension of the closing date will have a consequential effect on the date for the allotment and issue of New Shares. The timetable in respect of the Placement can only be amended by Next Science with the agreement of the Lead Managers.*

Next Science Investor Hub

Next Science welcomes direct engagement and encourages shareholders and interested parties to visit the Next Science Investor Hub which provides additional background information, videos and a forum for stakeholders to communicate with each other and with the Company. Stakeholders can access the Investor Hub through the following link: <https://investorhub.nextscience.com/announcements>

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Approved and authorised for release by the Managing Director and CEO.



About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com